What is the current stock price of Century Therapeutics, Inc. (IPSC)?

As of the latest market data, Century Therapeutics, Inc. (IPSC) is trading at $2.42. The stock has seen a gain of 11.75% today.

Does Century Therapeutics, Inc. (IPSC) pay a dividend?

Based on current data, Century Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Century Therapeutics, Inc.?

The current market capitalization of Century Therapeutics, Inc. (IPSC) is approximately unavailable.

IPSC

Century Therapeutics, Inc.·Healthcare

2.43

11.751%(+0.26)

Market Open

Last Updated: — ET

52W L: $0.4352W H: $3.04

IPSC NEWS

globenewswire.com

May 14

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors.

globenewswire.com

May 13

Century Therapeutics Reports First Quarter Financial Results and Business Updates

PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.

globenewswire.com

Apr 30

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026

seekingalpha.com

Apr 24

Century Therapeutics: A Biotech With Interesting Optionality Opportunities

Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813 for Type 1 diabetes, now the pipeline's main value driver. Recent management actions reduced quarterly cash burn from $35M to $20M, extending runway to Q1 2028 after a 134% dilutive PIPE.

defenseworld.net

Mar 5

Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.80

Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy

Company Profile

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

140

IPO Date

2021-06-18

Beta

1.56

Websitewww.centurytx.com↗